EKOS® Control Unit **4.0**

New EKOS® Control Unit 4.0 delivers bilateral workflow intelligence and integration.

Control Unit 4.0 vs. PT-3B

FEATURES	CONTROL UNIT 4.0 BENEFITS	CONTROL UNIT 4.0	CONTROL UNIT PT-3B
Treatment options and efficiency	Now you can manage bilateral PE, DVT, and PAO cases with just one system. It's estimated that over 80% of PE and ~30% of DVT cases are bilateral.	Powers and manages two EKOS® Devices simultaneously.	Powers one EKOS® Device.
Maneuverability and storage	Control Unit 4.0 is half the weight and one-third the size of PT-3B—making it easier to store, move, and use.	4.0 x 10.5 x 8.3 inches (H x W x D) 8.65 lbs.	8.5 x 12 x 14.25 inches (H x W x D) 17.4 lbs.
Portability and flexibility	This built-in flexibility and portability allow clinicians to better integrate Control Unit 4.0 into a hospital's workflow.	Built-in mounting bracket helps secure the Control Unit to an infusion stand while the integrated handle makes it easier to carry.	Doesn't mount to an infusion stand or have a carrying handle.
Battery power	Internal battery makes it easier to transport patients from Cath Lab to ICU with no interruption in therapy.	The unit has a built-in lithium-ion battery.	Requires large, external UPS backup to support therapy during transport.
Ease-of-use and time-to-treatment	Speeds time to starting treatment and makes troubleshooting easier.	Displays step-by-step, on-screen instructions using clear language and standardized, color-coded symbols. Provides real-time feedback, monitors therapy, and offers instructions for immediate corrective operation.	Dashboard interface displays basic operation of the unit and treatment run times.
Non-technical setup training	First-time users have found it easy to set up Control Unit 4.0 with limited or no advance training.	Comprehensive setup, operation, and troubleshooting instructions appear on screen; Control Unit 4.0 displays appropriate next steps to deliver therapy.	Training required prior to operation as dashboard does not display instructions for setup.
Upgradable	Control Unit 4.0 has extensibility built in. It has enough memory and power to accommodate future therapies, providing a longer, relevant shelf-life for hospitals.	Designed to work with current devices and supports future device innovation.	Not upgradable.

Bilateral PE treatment, simplified.



FDA CLEARED INDICATIONS: The EkoSonic® Endovascular System is intended for controlled and selective infusion of physician-specified fluids, including thrombolytics, into the peripheral vasculature. The EkoSonic® Endovascular System is intended for the infusion of solutions into the pulmonary arteries. The EkoSonic® Endovascular System is indicated for the ultrasound-facilitated, controlled and selective infusion of physician-specified fluids, including thrombolytics, into the vasculature for the treatment of pulmonary embolism.

CONTRAINDICATIONS: Not designed for peripheral vasculature dilatation purposes. The system is contraindicated when, in the medical judgement of the physician, such procedure may compromise the patient's condition. See device instructions for use for complete prescribing information.

BTG

EKOS CORPORATION | 11911 N. Creek Pkwy S. | Bothell, WA 98011 | 888.400.3567 | **EKOSCORP.COM**

EKOS and EkoSonic are registered trademarks of EKOS Corporation, a BTG International group company. "Acoustic pulse thrombolysis" is a trademark of EKOS Corporation. BTG and the BTG roundel logo are registered trademarks of BTG International Ltd in US, EU, and certain other territories and trademarks of BTG International Ltd elsewhere. All rights reserved. Copyright © 2017 EKOS Corporation. NA-EKO-2017-0358